Experimental Studies AT 1 Angiotensin II Receptor Inhibition in Pacing- Induced Heart Failure: Effects on Left Ventricular Performance and Regional Blood Flow Patterns

Background: AT l angiotensin II (AT I Ang II) receptor activation has been shown to cause increased vascular resistance in the systemic (SVR), pulmonary (PVR), and coronary vasculature which may be of particular importance in the setting of congestive heart failure (CHF). The overall goal of this study was to examine the effects of acute AT 1 Ang II receptor inhibition on left ventricular (LV) pump function, systemic hemodynamics, and regional blood flow patterns in the normal state and with CHF, both at rest and with treadmill-induced exercise. Methods and Results: Pigs (25 kg) were instrumented to measure cardiac output (CO), SVR, and PVR, and LV myocardial blood flow distribution in the conscious state and were assigned to one of two groups: (1) pacing-induced CHF (240 bpm for 3 weeks, n = 6) or (2) sham controls (n = 5). Measurements were obtained at rest and after treadmill exercise (15 ° for 10 minutes). Studies were repeated 30 minutes after intravenous infusion of a low (1.1 mg/kg) or high (125 mg/kg) dose of the AT~ Ang II antagonist, valsartan. The low dose of valsartan reduced the Ang II pressor response by approximately 50% but had a minimal effect on arterial pressure, whereas the high dose eliminated the Ang II pressor response and reduced resting blood pressure by approximately 20%. With CHF, CO was reduced at rest (2.5 -+ 0.2 v 3.9 -+ 0.1 L/rain) and with exercise (6.4 _+ 0.5 v 7.8 + 0.5 L/min) compared with controls (P < .05). Valsartan at the low and high dose increased resting CO by 28% in the control and CHF groups, but did not affect CO with exercise. Resting SVR in the CHF group was higher <

[1]  S. Whitebread,et al.  Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes. , 1997, Circulation.

[2]  B. Lévy,et al.  In vitro modulation of a resistance artery diameter by the tissue renin-angiotensin system of a large donor artery. , 1997, Circulation research.

[3]  Spinale Fg,et al.  The identification of contributory mechanisms for the development and progression of congestive heart failure in animal models. , 1996 .

[4]  J. D. Symons,et al.  Effects of angiotensin II receptor blockade during exercise: comparison of losartan and saralasin. , 1996, Journal of cardiovascular pharmacology.

[5]  N. Ohte,et al.  Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. , 1996, Circulation research.

[6]  J. Ménard,et al.  Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. , 1995, Circulation.

[7]  D. Neglia,et al.  Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. , 1995, Circulation.

[8]  Jennifer D. Walker,et al.  Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. , 1995, Circulation.

[9]  G. Zhao,et al.  Selective impairment of vagally mediated, nitric oxide-dependent coronary vasodilation in conscious dogs after pacing-induced heart failure. , 1995, Circulation.

[10]  T. Parrish,et al.  Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. , 1995, Circulation.

[11]  K. Dickstein,et al.  Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. , 1995, Circulation.

[12]  F W Prinzen,et al.  Developments in non-radioactive microsphere techniques for blood flow measurement. , 1994, Cardiovascular research.

[13]  T. Ehring,et al.  Attenuation of Myocardial Stunning by the ACE Inhibitor Ramiprilat Through a Signal Cascade of Bradykinin and Prostaglandins but not Nitric Oxide , 1994, Handbook of Experimental Pharmacology.

[14]  O. Carretero,et al.  A local kallikrein-kinin system is present in rat hearts. , 1994, Hypertension.

[15]  M. Kinoshita,et al.  Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.

[16]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[17]  T. Unger,et al.  Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. , 1994, Hypertension.

[18]  R. Cooper,et al.  Use of fluorescent latex microspheres to measure coronary blood flow distribution. , 1993, Circulatory shock.

[19]  S. Whitebread,et al.  Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype , 1993, British journal of pharmacology.

[20]  S. Yusuf,et al.  Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry , 1993 .

[21]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[22]  J. Cohn,et al.  Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.

[23]  R W Glenny,et al.  Validation of fluorescent-labeled microspheres for measurement of regional organ perfusion. , 1993, Journal of applied physiology.

[24]  L. Juillerat-Jeanneret Modulation of proteolytic activity in tissues following chronic inhibition of angiotensin-converting enzyme. , 1993, Biochemical pharmacology.

[25]  P. Yock,et al.  Effect of Selective Angiotensin II Receptor Antagonism and Angiotensin Converting Enzyme Inhibition on the Coronary Vasculature In Vivo Intravascular Two‐dimensional and Doppler Ultrasound Studies , 1993, Circulation.

[26]  S. Yusuf,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.

[27]  M. Noble,et al.  Haemodynamic and neurohumoral response in heart failure produced by rapid ventricular pacing. , 1992, Cardiovascular research.

[28]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[29]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[30]  J. Longhurst,et al.  Effect of long-term exercise on regional myocardial function and coronary collateral development after gradual coronary artery occlusion in pigs. , 1990, Circulation.

[31]  A. Nitenberg,et al.  Coronary vasodilation induced by intracoronary enalaprilat: an argument for the role of a local renin-angiotensin system in patients with dilated cardiomyopathy. , 1989, European heart journal.

[32]  J. Wilson,et al.  Effect of experimental heart failure on peripheral sympathetic vasoconstriction. , 1988, The American journal of physiology.

[33]  P. Armstrong,et al.  Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. , 1986, Circulation.

[34]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[35]  C. Bloor,et al.  The pig as a model for myocardial ischemia and exercise. , 1986, Laboratory animal science.

[36]  B. Lorell,et al.  Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: comparison with nitroprusside. , 1985, Journal of the American College of Cardiology.

[37]  P. Blankestijn,et al.  Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. , 1995, Hypertension.

[38]  V. Dzau Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. , 1993, Basic research in cardiology.

[39]  B. Strauer,et al.  ACE-inhibitors and coronary microcirculation. , 1993, Basic research in cardiology.

[40]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.